Overview Performance Dividends Peer Group Options

(BNTX) BioNTech SE - Ratings and Ratios

Exchange: NASDAQ • Country: Germany • Currency: USD • Type: Common Stock • ISIN: US09075V1026

Cancer, Immunotherapy, Vaccines, Oncology, Biotechnology

BNTX EPS (Earnings per Share)

EPS (Earnings per Share) of BNTX over the last years for every Quarter: "2020-03": -0.24, "2020-06": -0.38, "2020-09": -0.87, "2020-12": 1.54, "2021-03": 4.39, "2021-06": 10.77, "2021-09": 12.35, "2021-12": 12.19, "2022-03": 14.24, "2022-06": 6.45, "2022-09": 6.98, "2022-12": 9.26, "2023-03": 2.05, "2023-06": -0.79, "2023-09": 0.66, "2023-12": 1.9, "2024-03": -1.31, "2024-06": -3.36, "2024-09": 0.8, "2024-12": 1.08, "2025-03": -1.73,
EPS Growth (4Y CAGR): -21.24%
EPS Trend (4Y Correlation): -89.2%
EPS Growth Momentum (3Y): 31.0%

BNTX Revenue

Revenue of BNTX over the last years for every Quarter: 2020-03: 27.663, 2020-06: 41.762, 2020-09: 67.458, 2020-12: 345.442, 2021-03: 2048.4, 2021-06: 5308.5, 2021-09: 6087.3, 2021-12: 5532.5, 2022-03: 6374.6, 2022-06: 3196.5, 2022-09: 3461.2, 2022-12: 4278.3, 2023-03: 1277, 2023-06: 167.7, 2023-09: 895.3, 2023-12: 1479, 2024-03: 187.6, 2024-06: 128.7, 2024-09: 1244.8, 2024-12: 1190, 2025-03: 182.8,
Revenue Growth (4Y CAGR): -56.92%
Revenue Trend (4Y Correlation): -77.0%
Revenue Growth Momentum (3Y): 44.0%

Description: BNTX BioNTech SE

BioNTech SE is a German biotechnology company that is revolutionizing the field of immunotherapy, with a focus on developing innovative treatments for cancer and infectious diseases. With a robust pipeline of clinical-stage assets, the company is poised for significant growth and has the potential to disrupt the status quo in the pharmaceutical industry.

The companys diverse portfolio of immunotherapies includes BNT111, BNT113, and BNT311/GEN1046 (acasunlimab), which are in advanced stages of clinical trials for various types of cancer, including melanoma, head and neck squamous cell carcinoma, and solid tumors. Other notable candidates include BNT211, BNT221, and BNT327, which are being developed for the treatment of CLDN6+ solid tumors, cancer, and small cell lung cancer, among others.

From a technical analysis perspective, BNTX has shown significant price momentum, with a current price of $115.64 and a 20-day SMA of $98.06, indicating a potential bullish trend. The stock has also demonstrated a high level of volatility, with an ATR of 6.26, representing a 5.42% daily price swing. Given the current technical indicators, it is likely that BNTX will continue to experience price fluctuations in the short term.

Fundamentally, BioNTech SE has a market capitalization of $23.69B USD, with a forward P/E ratio of 7.04, indicating a relatively undervalued stock. The companys lack of profitability is reflected in its negative RoE of -4.02. However, with a robust pipeline of clinical-stage assets and a strong partnership with Pfizer, BioNTech SE is well-positioned for future growth.

Based on the technical and fundamental data, our forecast suggests that BNTX will experience a significant price increase in the next 6-12 months, driven by the potential approval of its lead candidates and the continued growth of its immunotherapy pipeline. With a target price of $140-$160, BNTX presents a compelling investment opportunity for those looking to capitalize on the growth potential of the biotechnology sector.

Additional Sources for BNTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

BNTX Stock Overview

Market Cap in USD 25,655m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2019-10-10

BNTX Stock Ratings

Growth Rating 9.82
Fundamental -55.2
Dividend Rating 1.0
Rel. Strength 47.7
Analysts 4.38 of 5
Fair Price Momentum 99.18 USD
Fair Price DCF -

BNTX Dividends

Currently no dividends paid

BNTX Growth Ratios

Growth Correlation 3m 60.1%
Growth Correlation 12m 14.8%
Growth Correlation 5y -29.8%
CAGR 5y 10.91%
CAGR/Max DD 5y 0.13
Sharpe Ratio 12m -0.77
Alpha 21.19
Beta 1.164
Volatility 58.62%
Current Volume 613.7k
Average Volume 20d 680.2k
What is the price of BNTX shares?
As of July 05, 2025, the stock is trading at USD 110.00 with a total of 613,718 shares traded.
Over the past week, the price has changed by +3.07%, over one month by -1.03%, over three months by +24.93% and over the past year by +37.35%.
Is BioNTech SE a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, BioNTech SE (NASDAQ:BNTX) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -55.17 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BNTX is around 99.18 USD . This means that BNTX is currently overvalued and has a potential downside of -9.84%.
Is BNTX a buy, sell or hold?
BioNTech SE has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy BNTX.
  • Strong Buy: 13
  • Buy: 3
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for BNTX share price target?
According to our own proprietary Forecast Model, BNTX BioNTech SE will be worth about 118.6 in July 2026. The stock is currently trading at 110.00. This means that the stock has a potential upside of +7.79%.
Issuer Target Up/Down from current
Wallstreet Target Price 136.9 24.4%
Analysts Target Price 135.6 23.2%
ValueRay Target Price 118.6 7.8%